20537 ⎘
Medicinal preparations containing organic active ingredients; Carbohydrates; Sugars; Derivatives thereof; Compounds having three or more nucleosides or nucleotides Double-stranded nucleic acids or oligonucleotides
ANTISENSE NUCLEIC ACIDS
#902COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA
#903METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES
#904SINGLE-NUCLEI CHARACTERIZATION OF AMYOTROPHIC LATERAL SCLEROSIS FRONTAL CORTEX
#905MIR-181 INHIBITORS AND USES THEREOF
#906COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRAS ASSOCIATED DISEASES OR DISORDERS
#907Exosome-targeted DNA vaccine
#908IMPROVED SURVIVAL OF HUMAN CELLS DIFFERENTIATED IN VITRO BY PRPF31 GENE EXPRESSION KNOCKDOWN
#909Therapeutic targets for facioscapulohumeral muscular dystrophy
#910Agents and methods for treating pancreatic ductal adenocarcinomas
#911RSK INHIBITORS IN THE TREATMENT OF VIRUS DISEASES
#912HIGH DENSITY LIPOPROTEIN MIMETIC NANOPARTICLES USING LIPID CONJUGATED CORE SCAFFOLDS
#913MODIFIED MICRORNAS AND THEIR USE IN THE TREATMENT OF CANCER
#914OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
#915CTLA-4 aptamer conjugates
#916RNA sequence adaptation
#917siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer
#918TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS
#919Carbohydrate conjugates as delivery agents for oligonucleotides
#920Sequence specific antimicrobials
#921Compositions for treating heart disease by inhibiting the action of mAKAP-β
#922RNA and nucleic acid carrier including the same
#923METHODS OF TREATING BREAST CANCER
#924USE OF THE MIR-27A-5P MICRORNA FOR TREATING CLOSTRIDIUM DIFFICILE-INDUCED BOWEL INFLAMMATION
#925METHODS TO IDENTIFY AND TREAT CISPLATIN-RESISTANT OVARIAN CANCER
#926Large Scale Synthesis of Messenger RNA
#927TARGETING SENESCENT CELLS
#928DIAGNOSIS AND TREATMENT OF MEDULLOBLASTOMA
#929INHIBITION OF LET7I AS A MEANS TO ENHANCE THE PROTECTIVE EFFECT OF PROGESTERONE AGAINST STROKE
#930Compositions and methods of treating muscle atrophy and myotonic dystrophy
#931METHODS FOR TREATING MACROPHAGE-MEDIATED DISEASES, AND METHODS OF IDENTIFYING AGENTS USEFUL THEREFORE
#932CATIONIC LIPIDS CONTAINING SILICON
#933KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#934NUCLEIC ACID CONJUGATE
#935Biodegradable lipids for the delivery of active agents
#936COMPOSITIONS AND METHODS FOR TREATING CANCER
#937EXTRAHEPATIC DELIVERY
#938Polycomb-associated Non-Coding RNAs
#939ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#940COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES, OBESITY, HYPER-CHOLESTEROLEMIA, AND ATHEROSCLEROSIS BY INHIBITION OF SAM68
#941Chimeric receptor binding proteins resistant to proteolytic degradation
#942DOUBLE STRANDED OLIGONUCLEOTIDE CONSTRUCT COMPRISING ANDROGEN RECEPTOR SPECIFIC SEQUENCE, AND COMPOSITION FOR PREVENTING HAIR LOSS AND PROMOTING HAIR GROWTH COMPRISING SAME
#943TARGETED POLYMERIZED NANOPARTICLES FOR CANCER TREATMENT
#944Compositions and methods for delivery of nucleic acid-lipid nanoparticle complexes encoding for viral RNA polymerase region and protein antigen
#945RNAi Inhibition of Alpha-ENaC Expression
#946METHODS FOR DIAGNOSING AND TREATING METASTATIC CANCER
#947METHODS FOR REDUCING POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD)
#948Lipid nanoparticle compositions and methods for mRNA delivery
#949LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY
#950Lipid nanoparticle compositions and methods for MRNA delivery
#951Biodegradable lipids for the delivery of active agents
#952COMPOSITIONS AND METHODS FOR DELIVERY OF RNA
#953DUX4 RNA Silencing Using RNA Targeting CRISPR-CAS13b
#954Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
#955Lipid nanoparticle compositions and methods for mRNA delivery
#956COMPOSITION, METHOD AND USE THEREOF
#957Biodegradable lipids for the delivery of active agents
#958PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS AND USES THEREFOR
#959Compositions of DNA molecules, methods of making therefor, and methods of use thereof
#960COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
#961mRNA combination therapy for the treatment of cancer
#962RNA-lipid nanoparticle complexes of viral RNA polymerase region and SARS-CoV-2 spike protein region
#963COMPOSITIONS AND METHODS FOR CANCER THERAPY
#964FABP4 as a therapeutic target in skin diseases
#965BLOOD-BRAIN BARRIER PERMEABILITY REGULATOR AND USE THEREOF
#966VIRAL VECTOR COMBINING GENE THERAPY AND GENOME EDITING APPROACHES FOR GENE THERAPY OF GENETIC DISORDERS
#967IDENTIFICATION OF MOLECULAR PATHWAYS AND METHODS OF USE THEREOF FOR TREATING RETINAL NEURODEGENERATION AND OTHER NEURODEGENERATIVE DISORDERS
#968Compositions and methods for reactivating latent immunodeficiency virus
#969Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
#970Method of treating fatty liver disease
#971Complement component C5 iRNA compositions and methods of use thereof
#972PH-sensitive and bioreducible polymer-virus complex for cancer treatment
#973METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES
#974METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES
#975ANTISENSE OLIGOMERS FOR TREATMENT OF AUTOSOMAL DOMINANT MENTAL RETARDATION-5 AND DRAVET SYNDROME
#976Medicinal composition comprising a non-coding RNA molecule and an antibody targeting a tumor antigen
#977IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT
#978USB1 directed regulation of miRNAs related hematopoietic differentiation and affected in multiple forms of leukemia
#979TFAP2 INHIBITION FOR TREATING CARDIAC DISEASE INVOLVING FIBRO-FATTY REPLACEMENT
#980DOUBLE-STRANDED OLIGONUCLEOTIDE TARGETING DKK1 GENE, CONSTRUCT INCLUDING SAME, AND HAIR LOSS PREVENTION OR HAIR GROWTH COMPOSITION CONTAINING SAME
#981COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASES OR CONDITIONS
#982RNA INTERFERENCE COMPOSITIONS AND METHODS FOR MALIGNANT TUMORS
#983SERPINC1 iRNA Compositions and Methods of Use Thereof
#984METHODS OF DELIVERING OLIGONUCLEOTIDES TO IMMUNE CELLS
#985USES OF PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS
#986Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#987Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#988Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#989Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#990Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#991Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#992Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat
#993Nucleic acid-polypeptide compositions and methods of inducing exon skipping
#994CARDIOSPHERE-DERIVED CELLS AND EXOSOMES SECRETED BY SUCH CELLS IN THE TREATMENT OF MUSCULAR DYSTROPHY
#995Pharmaceutical composition for preventing or treating liver cancer
#996TREATMENT OF SPINAL CONDITIONS WITH CHIMERA DECOY
#997Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
#998COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION
#999Methods of Treatment, Prevention and Diagnosis
#1000Compositions and methods for organ specific delivery of nucleic acids
#1001METHODS OF TREATMENT AND DIAGNOSIS OF TUMOURS
#1002Application of ERH gene in the preparation of bladder cancer diagnosis and treatment products
#1003Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1004Compositions and methods for dengue virus chimeric constructions in vaccines
#1005Dosage form for treating severe asthma
#1006Methods for improving exercise tolerance in myalgic encephalomyelitis patients
#1007SiRNA delivery system compound as well as preparation method and application thereof
#1008METHODS OF DETECTING AND REDUCING CANCER CELL CENTRAL NERVOUS SYSTEM COLONIZATION
#1009MEANS AND METHODS FOR REDUCING TUMORIGENICITY OF CANCER STEM CELLS
#1010RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use
#1011HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE
#1012REGULATION OF NUCLEOTIDE EXCISION REPAIR (NER) BY MICRORNA FOR TREATMENT OF CANCER
#1013PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS
#1014EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1015Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
#1016ANTIBODY-DRUG CONJUGATES AND USES THEREOF
#1017Immunoregulatory agent
#1018Nanostructured lipid carriers and stable emulsions and uses thereof
#1019KLF11 siRNA for treatment of diabetes and obesity
#1020CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
#1021Methods for Promoting Reinnervation of Auditory Hair Cells
#1022Treatment of staphylococcal disorders
#1023COMBINATION THERAPY
#1024ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS
#1025Nucleic acid nanocarrier drug, preparation method, pharmaceutical composition and use thereof
#1026Drug Delivery Particle and Method for Producing the Same
#1027RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1028Lipid nanoparticle compositions and methods for mRNA delivery
#1029Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1030Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1031Methods, agents and compositions as in situ vaccine for cancer cell and tumor treatment
#1032Compositions and methods for delivery of biomacromolecule agents
#1033Methods of treatment using cholestosome vesicles for incorporation of molecules into chylomicrons
#1034PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FABRY DISEASE, CONTAINING TSP1 PROTEIN INHIBITOR AS ACTIVE INGREDIENT
#1035Expression of miRNAs in Placental Tissue
#1036Targeting Ligands
#1037METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MLH1 ACTIVITY
#1038COMPOSITIONS AND METHODS FOR MODULATION OF LMNA EXPRESSION
#1039TRPC ion channel inhibitors for use in therapy
#1040Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease
#1041METHODS OF TREATING SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC DISORDERS
#1042Antisense oligomers targeting PCSK9
#1043COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID ANTICOAGULANTS
#1044METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
#1045Inhibition of cytokine-induced SH2 protein in NK cells
#1046Inhibition of cytokine-induced SH2 protein in NK cells
#1047Alpha-v beta-6 integrin ligands and uses thereof
#1048Lipids and compositions for the delivery of therapeutics
#1049SYNTHETIC LETHALITY AND THE TREATMENT OF CANCER
#1050Stable formulations of lipids and liposomes
#1051METHODS FOR IDENTIFYING THERAPEUTIC TARGETS AND TREATING AND MONITORING CANCERS
#1052METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER
#1053DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS
#1054RNAI MOLECULE FOR TREATING CANCER
#1055Composition for Inhibiting Replication of Hepatitis B Virus
#1056Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1057Carbohydrate conjugates as delivery agents for oligonucleotides
#1058INHIBIN AS TARGETABLE REGULATORS OF ANGIOGENESIS
#1059Composition comprising aptamer as active ingredient for treatment and prevention of degenerative brain disease
#1060COMPOSITIONS AND METHODS FOR CONTROLLING ARTHORPOD PARASITE AND PEST INFESTATIONS
#1061CATIONIC LIPID COMPOSITIONS FOR TISSUE-SPECIFIC DELIVERY
#1062Lipid nanoparticle formulations
#1063COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE
#1064Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer
#1065Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1066COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION
#1067METHODS FOR REDUCTION OF PATHOLOGICAL FIBROSIS AND ASSOCIATED DISORDERS AND DISEASES
#1068Pharmaceutical compositions, vaccines and their uses in the prevention or treatment of a persistent infection or of cancer
#1069NANOPLEXED POLY(I:C) FORMULATIONS AND USES THEREOF
#1070VDAC1 SILENCING MOLECULES AND USE THEREOF
#1071COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
#1072Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
#1073COMPOSITIONS FOR HERPESVIRUS TRANSCRIPTIONAL FEEDBACK CIRCUIT DISRUPTION AND USES THEREOF
#1074RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION
#1075COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#1076Monocarboxylate transporter (MCT) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
#1077Cross-linked polymer modified nanoparticles
#1078Methods for sustainable human cognitive enhancement
#1079Compositions and methods for immune cell modulation in adoptive immunotherapies
#1080METHODS AND COMPOSITIONS FOR TREATING HEMOPHILIA
#1081Protection of cells from degeneration and treatment of geographic atrophy
#1082THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
#1083Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1084Methods of Manipulating the Fate of Cells
#1085COMPOSITION FOR PREVENTING OR TREATING KELOIDS OR HYPERTROPHIC SCARS
#1086METHOD OF TREATING A LOCALIZED FIBROTIC DISORDER USING A TNF RECEPTOR 2 ANTAGONIST
#1087METHODS FOR TREATING CANCER WITH DOUBLE STRANDED RNA SENSOR ACTIVATORS AND ADOPTIVE CELL THERAPY
#1088MULTIMERIC OLIGONUCLEOTIDES HAVING DECREASED KIDNEY CLEARANCE
#1089Anti-PD-L1 antibody and use thereof
#1090Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
#1091High efficiency aptamer complex comprising branched DNA and aptamer, and use thereof
#1092METHOD AND MEANS TO DELIVER miRNA TO TARGET CELLS
#1093DOUBLE-STRANDED OLIGO RNA STRUCTURE COMPRISING miRNA
#1094Methods for treating or preventing ophthalmological conditions
#1095Physiologically active substance carrier
#1096CYCLOPHILIN 40 FOR REDUCTION OF NEUROTOXIC FIBRILS AND TREATMENT OF NEURODEGENERATIVE DISEASES
#1097ENHANCED CANCER TREATMENT AND MONITORING USING RECOMBINANT VECTORS
#1098OLIGONUCLEOTIDES FOR MSH3 MODULATION
#1099Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition
#1100METHODS AND REAGENTS TO TREAT ALLERGY
#1101Lipid Nanoparticle Formulations for mRNA Delivery
#1102Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
#1103siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
#1104The Microbiome as a Target of MicroRNAs for the Treatment of Disease
#1105NANOHYDROXYAPATITE NANOCARRIER FOR GENETIC CARGO
#1106GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
#1107Allele specific modulators of P23H rhodopsin
#1108COMBINATION IMMUNOTHERAPIES
#1109UNIMOLECULAR NANOPARTICLES FOR EFFICIENT DELIVERY OF THERAPEUTIC RNA
#1110DELIVERY OF DNA
#1111Modified AAV constructs and uses thereof
#1112ESOPHAGEAL CANCER MARKER AND USE THEREOF
#1113COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY
#1114Liposomes comprising polymer-conjugated lipids and related uses
#1115ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ORAL MUCOSITIS
#1116Control of replication and transcription of self-replicating RNA in response to small molecules
#1117SILENCING TGF-BETA 1 and COX2 USING siRNAs DELIVERED in a POLYPEPTIDE NANOPARTICLE ALONE and in COMBINATION with IMMUNE CHECKPOINT INHIBITORS to TREAT CANCER
#1118MODULATING IMMUNE RESPONSES
#1119Sequence specific antimicrobials
#1120Hippo regulation of cardiac vascularity, fibrosis, and inflammation
#1121USE OF AKT INHIBITORS IN OPHTHALMOLOGY
#1122BIOMARKERS, COMPOSITIONS, AND METHODS FOR DIAGNOSING AND TREATING SUBJECTS EXPOSED TO PROTEIN/HEPARIN COMPLEXES
#1123OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND USES THEREOF
#1124ANTISENSE OLIGONUCLEOTIDE (ASO) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES
#1125SERPINA1 iRNA compositions and methods of use thereof
#1126Compounds and Methods for Modulation of Transcript Processing
#1127MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
#1128Methods and pharmaceutical compositions for treating lymphoid malignancy
#1129USE OF TROP-2 AS PREDICTIVE MARKER OF RESPONSE TO ANTI-TUMOR THERAPY BASED ON INHIBITORS OF CD9, AKT AND MOLECULES OF THE TETRASPANIN SIGNALLING NETWORK
#1130Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders
#1131METHODS FOR COMBINATORIAL SCREENING AND USE OF THERAPEUTIC TARGETS THEREOF
#1132COMPOSITIONS AND METHODS FOR TREATING A TUMOR SUPPRESSOR DEFICIENT CANCER
#1133DNA aptamers, method for inhibiting human galectin-1 and method of treating a mammal in need thereof
#1134Lipid nanoparticle compositions and methods for mRNA delivery
#1135Composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA
#1136Inducing proliferation of cardiomyocytes and therapeutic uses related thereto
#1137Method for producing dextran polymer-based, amplified nucleic acid aptamer nanoconstruct selectively capturing target molecule
#1138Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1139AMINE CATIONIC LIPIDS AND USES THEREOF
#1140MODULATION OF LNC05 EXPRESSION
#1141METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH CORTICO-HIPPOCAMPAL HYPERACTIVITY
#1142METHODS OF SUPPRESSING DELIVERY OF EXOSOMES TO LIVER AND SPLEEN
#1143Long double-stranded RNA for RNA interference
#1144COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION
#1145Methods for treating hepatitis B infection
#1146METHOD FOR TREATING ASTHMA OR ALLERGIC DISEASE
#1147METHODS OF TREATING CLRN1-ASSOCIATED HEARING LOSS AND/OR VISION LOSS
#1148Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
#1149Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
#1150COMPOSITIONS AND METHODS OF USE OF CRISPR-CAS SYSTEMS IN NUCLEOTIDE REPEAT DISORDERS
#1151COMPOSITIONS AND METHODS FOR TREATING A TUMOR SUPPRESSOR DEFICIENT CANCER
#1152COMPOSITIONS FOR CONFERRING TOLERANCE TO VIRAL DISEASE IN SOCIAL INSECTS, AND THE USE THEREOF
#1153Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
#1154Sideroflexins as mitochondrial serine transporters
#1155METHODS FOR TREATING PTEN DEFICIENT EPITHELIAL CANCERS USING A COMBINATION OF ANTI-PI3KBETA AND ANTI-IMMUNE CHECKPOINT AGENTS
#1156Lipid formulations for nucleic acid delivery
#1157Liver protective MARC variants and uses thereof
#1158Compositions and methods of inhibiting gene expression in a lung
#1159AAV CARDIAC GENE THERAPY FOR CARDIOMYOPATHY
#1160MEDICINE USING HSP47 INHIBITOR TO ENHANCE SENSITIVITY TO CHEMOTHERAPEUTIC AGENT
#1161RIG-I Agonists and Treatments Using Same
#1162Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making And Using Same
#1163COMPOSITIONS AND METHODS INVOLVING TRANSFORMING EXTRACELLULAR VESICLES
#1164SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1165Anti-NGF Antibodies and Methods Thereof
#1166Multicomponent degradable cationic polymers
#1167COMBINATION THERAPIES FOR INNER EAR SENSORY HAIR CELL REGENERATION/REPLACEMENT
#1168METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K)
#1169SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME
#1170Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV)
#1171Factor XII (Hageman Factor) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1172COMPOSITIONS AND METHODS FOR ANTI-LYST IMMUNOMODULATION
#1173METABOLICALLY STABILIZED DOUBLE STRANDED mRNA
#1174RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#1175Canine anti-NGF antibodies and methods of treating pain thereof
#1176EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
#1177PEPTIDE/PARTICLE DELIVERY SYSTEMS
#1178NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY
#1179COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
#1180Felinized anti-NGF antibodies and methods of treating pain
#1181Anti-NGF Antibodies and Methods Thereof
#1182Methods of treating a canine and inhibiting NGF activity through use of anti-NGF antibodies
#1183Compositions for Controlling Neuronal Outgrowth
#1184Treatments of non-alcoholic steatohepatitis (NASH)
#1185Nanovesicles derived from cell membrane, and use thereof
#1186AAV-COMPATIBLE LAMININ-LINKER POLYMERIZATION PROTEINS
#1187Non-liposomal systems for nucleic acid delivery
#1188Anti-CTLA4 antibodies and methods of making and using the same
#1189METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXBETA REDUCTASE
#1190METHODS FOR DETERMINING THE PRESENCE OR RISK OF DEVELOPING FACIOSCAPULOHUMERAL DYSTROPHY (FSHD)
#1191Humanized anti-NGF antibodies and methods of treating pain thereof
#1192COMPOSITIONS FOR CANCER THERAPY AND METHODS
#1193Pharmaceutical composition for preventing or treating dentin-dental pulp disease or periodontal disease, containing LPAR2 inhibitor
#1194Agents for improved delivery of nucleic acids to eukaryotic cells
#1195Targeting ligands for therapeutic compounds
#1196Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
#1197Nucleic acids encoding a canine antibody which binds nerve growth factor and vectors and host cells thereof
#1198Compositions and methods of treating muscle atrophy and myotonic dystrophy
#1199TALEN-BASED GENE CORRECTION
#1200Methods of treating cancers